The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Gastrointestinal Therapeutics and Diagnostics-Global Market Insights and Sales Trends 2025
Synopsis
Gastrointestinal disorders are related to digestive system and generally affect the colon, small & large intestine and rectum. The disorders include constipation, peptic ulcer diseases and irritable bowel syndrome. The major reason and cause of GI disorders are stress, intake of medicines such as iron pills and anti-depressants and unhealthy eating habits. Symptoms of the gastrointestinal infections include pain, bloating, diarrhea, nausea and vomiting. The major drugs that dominate the gastrointestinal diagnostics and therapeutics market are aciphex, afinitor, akynzeo, dificid and Prilosec.
The global Gastrointestinal Therapeutics and Diagnostics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Gastrointestinal Therapeutics and Diagnostics in various end use industries. The expanding demands from the Gastroenteritis, GI Bleeding, Irritable Bowel Syndrome and Peptic Ulcer Disease (PUD), are propelling Gastrointestinal Therapeutics and Diagnostics market. Diagnostics, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Therapeutics segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Gastrointestinal Therapeutics and Diagnostics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Gastrointestinal Therapeutics and Diagnostics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Gastrointestinal Therapeutics and Diagnostics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Gastrointestinal Therapeutics and Diagnostics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Gastrointestinal Therapeutics and Diagnostics covered in this report include Abbott Laboratories, AstraZeneca, Eisai, Johnson & Johnson, Salix Pharmaceuticals and Takeda Pharmaceutical Company, etc.
The global Gastrointestinal Therapeutics and Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott Laboratories
AstraZeneca
Eisai
Johnson & Johnson
Salix Pharmaceuticals
Takeda Pharmaceutical Company
Global Gastrointestinal Therapeutics and Diagnostics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Gastrointestinal Therapeutics and Diagnostics market, Segment by Type:
Diagnostics
Therapeutics
Global Gastrointestinal Therapeutics and Diagnostics market, by Application
Gastroenteritis
GI Bleeding
Irritable Bowel Syndrome
Peptic Ulcer Disease (PUD)
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Gastrointestinal Therapeutics and Diagnostics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Gastrointestinal disorders are related to digestive system and generally affect the colon, small & large intestine and rectum. The disorders include constipation, peptic ulcer diseases and irritable bowel syndrome. The major reason and cause of GI disorders are stress, intake of medicines such as iron pills and anti-depressants and unhealthy eating habits. Symptoms of the gastrointestinal infections include pain, bloating, diarrhea, nausea and vomiting. The major drugs that dominate the gastrointestinal diagnostics and therapeutics market are aciphex, afinitor, akynzeo, dificid and Prilosec.
The global Gastrointestinal Therapeutics and Diagnostics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Gastrointestinal Therapeutics and Diagnostics in various end use industries. The expanding demands from the Gastroenteritis, GI Bleeding, Irritable Bowel Syndrome and Peptic Ulcer Disease (PUD), are propelling Gastrointestinal Therapeutics and Diagnostics market. Diagnostics, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Therapeutics segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Gastrointestinal Therapeutics and Diagnostics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Gastrointestinal Therapeutics and Diagnostics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Gastrointestinal Therapeutics and Diagnostics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Gastrointestinal Therapeutics and Diagnostics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Gastrointestinal Therapeutics and Diagnostics covered in this report include Abbott Laboratories, AstraZeneca, Eisai, Johnson & Johnson, Salix Pharmaceuticals and Takeda Pharmaceutical Company, etc.
The global Gastrointestinal Therapeutics and Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott Laboratories
AstraZeneca
Eisai
Johnson & Johnson
Salix Pharmaceuticals
Takeda Pharmaceutical Company
Global Gastrointestinal Therapeutics and Diagnostics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Gastrointestinal Therapeutics and Diagnostics market, Segment by Type:
Diagnostics
Therapeutics
Global Gastrointestinal Therapeutics and Diagnostics market, by Application
Gastroenteritis
GI Bleeding
Irritable Bowel Syndrome
Peptic Ulcer Disease (PUD)
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Gastrointestinal Therapeutics and Diagnostics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Gastrointestinal Therapeutics and Diagnostics
1.1 Gastrointestinal Therapeutics and Diagnostics Market Overview
1.1.1 Gastrointestinal Therapeutics and Diagnostics Product Scope
1.1.2 Gastrointestinal Therapeutics and Diagnostics Market Status and Outlook
1.2 Global Gastrointestinal Therapeutics and Diagnostics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Gastrointestinal Therapeutics and Diagnostics Market Size by Region (2018-2029)
1.4 Global Gastrointestinal Therapeutics and Diagnostics Historic Market Size by Region (2018-2023)
1.5 Global Gastrointestinal Therapeutics and Diagnostics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Gastrointestinal Therapeutics and Diagnostics Market Size (2018-2029)
1.6.1 North America Gastrointestinal Therapeutics and Diagnostics Market Size (2018-2029)
1.6.2 Europe Gastrointestinal Therapeutics and Diagnostics Market Size (2018-2029)
1.6.3 Asia-Pacific Gastrointestinal Therapeutics and Diagnostics Market Size (2018-2029)
1.6.4 Latin America Gastrointestinal Therapeutics and Diagnostics Market Size (2018-2029)
1.6.5 Middle East & Africa Gastrointestinal Therapeutics and Diagnostics Market Size (2018-2029)
2 Gastrointestinal Therapeutics and Diagnostics Market by Type
2.1 Introduction
2.1.1 Diagnostics
2.1.2 Therapeutics
2.2 Global Gastrointestinal Therapeutics and Diagnostics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Gastrointestinal Therapeutics and Diagnostics Historic Market Size by Type (2018-2023)
2.2.2 Global Gastrointestinal Therapeutics and Diagnostics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Gastrointestinal Therapeutics and Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Gastrointestinal Therapeutics and Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Gastrointestinal Therapeutics and Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Gastrointestinal Therapeutics and Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Gastrointestinal Therapeutics and Diagnostics Revenue Breakdown by Type (2018-2029)
3 Gastrointestinal Therapeutics and Diagnostics Market Overview by Application
3.1 Introduction
3.1.1 Gastroenteritis
3.1.2 GI Bleeding
3.1.3 Irritable Bowel Syndrome
3.1.4 Peptic Ulcer Disease (PUD)
3.1.5 Others
3.2 Global Gastrointestinal Therapeutics and Diagnostics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Gastrointestinal Therapeutics and Diagnostics Historic Market Size by Application (2018-2023)
3.2.2 Global Gastrointestinal Therapeutics and Diagnostics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Gastrointestinal Therapeutics and Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Gastrointestinal Therapeutics and Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Gastrointestinal Therapeutics and Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Gastrointestinal Therapeutics and Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Gastrointestinal Therapeutics and Diagnostics Revenue Breakdown by Application (2018-2029)
4 Gastrointestinal Therapeutics and Diagnostics Competition Analysis by Players
4.1 Global Gastrointestinal Therapeutics and Diagnostics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Gastrointestinal Therapeutics and Diagnostics as of 2022)
4.3 Date of Key Players Enter into Gastrointestinal Therapeutics and Diagnostics Market
4.4 Global Top Players Gastrointestinal Therapeutics and Diagnostics Headquarters and Area Served
4.5 Key Players Gastrointestinal Therapeutics and Diagnostics Product Solution and Service
4.6 Competitive Status
4.6.1 Gastrointestinal Therapeutics and Diagnostics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Abbott Laboratories
5.1.1 Abbott Laboratories Profile
5.1.2 Abbott Laboratories Main Business
5.1.3 Abbott Laboratories Gastrointestinal Therapeutics and Diagnostics Products, Services and Solutions
5.1.4 Abbott Laboratories Gastrointestinal Therapeutics and Diagnostics Revenue (US$ Million) & (2018-2023)
5.1.5 Abbott Laboratories Recent Developments
5.2 AstraZeneca
5.2.1 AstraZeneca Profile
5.2.2 AstraZeneca Main Business
5.2.3 AstraZeneca Gastrointestinal Therapeutics and Diagnostics Products, Services and Solutions
5.2.4 AstraZeneca Gastrointestinal Therapeutics and Diagnostics Revenue (US$ Million) & (2018-2023)
5.2.5 AstraZeneca Recent Developments
5.3 Eisai
5.3.1 Eisai Profile
5.3.2 Eisai Main Business
5.3.3 Eisai Gastrointestinal Therapeutics and Diagnostics Products, Services and Solutions
5.3.4 Eisai Gastrointestinal Therapeutics and Diagnostics Revenue (US$ Million) & (2018-2023)
5.3.5 Johnson & Johnson Recent Developments
5.4 Johnson & Johnson
5.4.1 Johnson & Johnson Profile
5.4.2 Johnson & Johnson Main Business
5.4.3 Johnson & Johnson Gastrointestinal Therapeutics and Diagnostics Products, Services and Solutions
5.4.4 Johnson & Johnson Gastrointestinal Therapeutics and Diagnostics Revenue (US$ Million) & (2018-2023)
5.4.5 Johnson & Johnson Recent Developments
5.5 Salix Pharmaceuticals
5.5.1 Salix Pharmaceuticals Profile
5.5.2 Salix Pharmaceuticals Main Business
5.5.3 Salix Pharmaceuticals Gastrointestinal Therapeutics and Diagnostics Products, Services and Solutions
5.5.4 Salix Pharmaceuticals Gastrointestinal Therapeutics and Diagnostics Revenue (US$ Million) & (2018-2023)
5.5.5 Salix Pharmaceuticals Recent Developments
5.6 Takeda Pharmaceutical Company
5.6.1 Takeda Pharmaceutical Company Profile
5.6.2 Takeda Pharmaceutical Company Main Business
5.6.3 Takeda Pharmaceutical Company Gastrointestinal Therapeutics and Diagnostics Products, Services and Solutions
5.6.4 Takeda Pharmaceutical Company Gastrointestinal Therapeutics and Diagnostics Revenue (US$ Million) & (2018-2023)
5.6.5 Takeda Pharmaceutical Company Recent Developments
6 North America
6.1 North America Gastrointestinal Therapeutics and Diagnostics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Gastrointestinal Therapeutics and Diagnostics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Gastrointestinal Therapeutics and Diagnostics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Gastrointestinal Therapeutics and Diagnostics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Gastrointestinal Therapeutics and Diagnostics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Gastrointestinal Therapeutics and Diagnostics Market Dynamics
11.1 Gastrointestinal Therapeutics and Diagnostics Industry Trends
11.2 Gastrointestinal Therapeutics and Diagnostics Market Drivers
11.3 Gastrointestinal Therapeutics and Diagnostics Market Challenges
11.4 Gastrointestinal Therapeutics and Diagnostics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
